September 2026 Edition
About the Newsletter
Each edition draws from RegulatoryID, MedPro's expert-maintained reference covering transparency and compliance requirements across 50+ countries. The team that maintains the compendium also curates each newsletter, surfacing the deadlines, filings and rule changes most relevant to Life Sciences manufacturers, distributors and medical device companies in the month ahead.
What You Receive Each Month
A single monthly newsletter delivered the first Tuesday of each month, covering U.S. and international jurisdictions
Concise high-level summaries in the email so you can quickly scan deadlines and what's required
Linked detailed summaries with full regulatory context, deadlines and reference links
Immediate alerts for urgent developments that cannot wait for the next monthly send
Inside the September Edition
This month brings two disclosure updates across international jurisdictions, including one upcoming filing deadline and one annual disclosure requirement. Subscribe to access the full requirements, source links and submission details for each.
Colombia Biannual Disclosure Due 9/30
Pursuant to Resolution 2881 of 2018, healthcare companies domiciled in the national territory of Colombia must disclose Health Sector Value Transfers, made directly or indirectly, to reportable recipients once expenditures exceed a per recipient reporting threshold. Covered interactions taking place in the first half of 2026, between January 1 and June 30, are due to be disclosed by September 30, 2026 to Colombia’s Ministry of Health and Social Protection via the central platform, Registry of Value Transfers between Health Sector Actors available through the Information Exchange Platform of the Comprehensive Social Protection Information System.* Companies must disclose even if they have not provided any Health Sector Value Transfers during the respective reportable period.
*We are aware that the platform webpage is timing out while connecting and have reached out to the Ministry of Health and Social Protection regarding this.
Japan Annual Disclosure Reminder
Pursuant to the Clinical Research Act, license holders for the manufacture or sale of pharmaceuticals, medical devices or regenerative medicine products, or persons with a special relationship with such license holders, shall disclose all covered transfers of value made in the previous fiscal year to medical institutions, persons conducting Specific Clinical Research, or persons having a special relationship with persons conducting Specific Clinical Research on their company website, as enforced by the Ministry of Health, Labor and Welfare.
This disclosure must be made annually within one year from the date of a company’s fiscal year end.
Subscribe to the RegulatoryID Newsletter
Enter your work email to request access to the full September 2026 edition and to receive ongoing updates direct to your inbox.